Discovers, develops, and commercializes treatments for rare and orphan diseases. Sells Endari, an FDA-approved L-glutamine oral powder for sickle cell disease. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 12% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 6 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $7.5M against $12.5M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.05. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 8.9 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.